drugset
drugset / Trial / NCT04299880

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880 ↗

Phase 1 Completed 7 enrolled Sumitomo Pharma America, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated with napabucasin (monotherapy or combination) and who are deriving continued clinical benefit in the parent study at the time of closure.

Timeline

Start
2020-02-24
Primary completion
2021-05-15
Completion
2021-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Napabucasin Small molecule — Oral
Background Bevacizumab Monoclonal antibody — Intravenous
Background Gemcitabine Small molecule — Intravenous
Background Irinotecan Small molecule — Intravenous
Background Leucovorin Small molecule — Intravenous
Background Nivolumab Monoclonal antibody 3 mg/kg Intravenous
Background Paclitaxel Small molecule — Intravenous
Background fluorouracil Small molecule — Intravenous

Indications

No indication recorded.